Symeres (Mercachem)

Symeres is a leading transatlantic contract research, development, and manufacturing organization (CDMO/CRO) that supports pharmaceutical and biotechnology companies throughout the entire drug development lifecycle. Formed through the merger of Mercachem and Syncom, the company provides integrated services including medicinal chemistry, ADME-Tox, bioanalysis, process chemistry, solid-state chemistry, and GMP manufacturing. By combining deep technical expertise across laboratories in Europe and the United States, Symeres helps clients accelerate small-molecule drug candidates from early hit identification through IND-enabling studies and clinical supply.

The company serves as a vital partner for both emerging biotechs and global pharmaceutical organizations, helping them navigate complex scientific challenges and de-risk development programs. By offering flexible support models—ranging from standalone studies to fully integrated, end-to-end development programs—Symeres enables partners to improve decision-making, reduce development costs, and speed up the progression of transformative therapies into the clinic. Through its commitment to quality, regulatory alignment, and integrated workflows, Symeres ensures that molecules are prepared efficiently for successful clinical and commercial transition.